Health Economics›Peripheral T-cell lymphoma›Relapsed or refractory non-randomized or retrospective data

Relapsed or refractory non-randomized or retrospective data

Peripheral T-cell lymphoma · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Brentuximab vedotin monotherapy Variant #01	—	R 85 244	21d	~16.7 mo	—	~25	~R 2 131 097 PFS proxy · indirect	1
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	~39.0 mo	~113.8 mo	~14	~R 89 057 PFS proxy · indirect	10
Belinostat monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
Mogamulizumab monotherapy Variant #01 Partial	—	—	7d	~7.7 mo	—	~34	—	1
Duvelisib monotherapy Variant #01 Partial	—	—	28d	~13.3 mo	—	~15	—	1
Chidamide monotherapy Variant #01 Partial	—	—	7d	—	—	—	—	—
Forodesine monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Darinaparsin monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—

8 of 8 regimens shown